Your session is about to expire
← Back to Search
MyPath tool for Substance Use Disorder (EMERALD Trial)
N/A
Waitlist Available
Led By Beatrice A Chen, MD MPH
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately four months
Awards & highlights
EMERALD Trial Summary
Evaluating MyPath to Enhance Reproductive Autonomy and Liberate Decision-making
Eligible Conditions
- Substance Use Disorder
- Reproductive Issues
- Birth Control
EMERALD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately one month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately one month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants reporting satisfaction with MyPath assessed by 5-point Likert scale
Number of participants reporting satisfaction with reproductive discussions assessed by 5-point Likert scale
Number of providers reporting comfort with reproductive discussions assessed by 5-point Likert scale
+1 moreSecondary outcome measures
Mean change in decisional conflict
Mean change in reproductive health knowledge
Mean change in self-efficacy
+3 moreEMERALD Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Phase 3: MyPath PilotExperimental Treatment1 Intervention
Following completion of the usual care arm, the investogators will enroll a second group of 33 women with SUDs to participate in the MyPath intervention arm. Participants will complete the same pre-visit survey as the usual care group. In addition, they will be provided a website link to navigate through the online MyPath tool. Following completion of MyPath, participants will receive a summary page that they will be encouraged to use as a guide when discussing their reproductive health with their substance use treatment provider at their next scheduled therapy visit. After the visit, they will complete the post-visit survey. In addition to satisfaction with reproductive health services, the intervention group will be asked specific questions about their perception of the MyPath tool.
Group II: Phase 2: Usual CareActive Control1 Intervention
The investigators will enroll 33 women with SUDs to evaluate baseline family planning discussions and referrals to women's health providers in SUD treatment settings. To establish usual care practice patterns, MyPath will not be administered to this group of participants. Participants will be asked to complete a pre-visit survey, including substance use history and current reproductive health goals, as well as questions about reproductive health knowledge, self-efficacy, and decision conflict. The participants will then attend their scheduled therapy visit with the substance use treatment provider. Following the therapy visit, they will complete the post-visit survey, which will include the same knowledge, efficacy, and decision conflict survey questions as the pre-visit survey. Occurrence of reproductive health discussions, prescriptions or referrals, and satisfaction with reproductive health services will be measured following the visit as well.
Find a Location
Who is running the clinical trial?
Society of Family PlanningOTHER
98 Previous Clinical Trials
17,133 Total Patients Enrolled
University of PittsburghLead Sponsor
1,719 Previous Clinical Trials
16,342,340 Total Patients Enrolled
Beatrice A Chen, MD MPHPrincipal InvestigatorUniversity of Pittsburgh
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger